1. Home
  2. PVL vs CALC Comparison

PVL vs CALC Comparison

Compare PVL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

N/A

Current Price

$1.79

Market Cap

60.1M

Sector

Energy

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$5.09

Market Cap

63.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PVL
CALC
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.1M
63.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PVL
CALC
Price
$1.79
$5.09
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
74.4K
132.5K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
19.77%
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$3,511,891.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$28.44
N/A
Revenue Growth
11.77
N/A
52 Week Low
$1.30
$1.42
52 Week High
$2.04
$5.34

Technical Indicators

Market Signals
Indicator
PVL
CALC
Relative Strength Index (RSI) 44.86 65.93
Support Level $1.78 $4.24
Resistance Level $1.90 $5.34
Average True Range (ATR) 0.05 0.41
MACD -0.00 0.04
Stochastic Oscillator 17.26 73.24

Price Performance

Historical Comparison
PVL
CALC

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: